Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer

Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer

Background: Prostate cancer is the second most frequently diagnosed malignancy worldwide. Here, the cytotoxic and antimetastatic effects of a new HDAC6/8 inhibitor, LASSBio-1911, and a new dual-PI3K/HDAC6 inhibitor, LASSBio-2208, were evaluated against PC3 prostate cancer cell line. Methods: A MTT a...

Full description

Bibliographic Details
Main Authors: Fabiana Sélos Guerra, Daniel Alencar Rodrigues, Carlos Alberto Manssour Fraga, Patricia Dias Fernandes
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Pharmaceuticals
Subjects:
cancer
prostate cancer
PI3K
HDAC6
apoptosis
cell cycle
Online Access:https://www.mdpi.com/1424-8247/14/5/387

Similar Items

Similar Items